ClinConnect ClinConnect Logo
Search / Trial NCT02166554

The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions

Launched by BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD · Jun 16, 2014

Trial Information

Current as of June 02, 2025

Completed

Keywords

Adhesions Hyaluronan Gynaecological Surgery Clinical Outcomes

ClinConnect Summary

Postsurgical adhesions are a common medical complication of gynecologic and pelvic surgeries, and are frequently associated with chronic or recurrent pelvic pain, intestinal obstruction and infertility. This randomized, controlled, multicenter, clinical study was designed to evaluate the safety and performance of the new crosslinked hyaluronan hydrogel versus the standard of care for the reduction of postoperative adhesions in subjects undergoing laparoscopic surgeries. Subjects were scheduled to return at 9 weeks after the initial surgical procedure. At that time, a second-look laparoscopy...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Female.
  • Aged 18-45 years.
  • Been scheduled for removal of myomas, ovary cysts, endometriotic cysts or adhesions.
  • Been willing to comply with all aspects of the treatment and evaluation schedule.
  • Agreed to a second-look laparoscopic procedure to assess and lyse any adhesions formed at 9 weeks following the primary surgery.
  • Provided voluntary written informed consent.
  • Exclusion Criteria:
  • Acute or severe infection.
  • Autoimmune diseases such as diabetes etc.
  • Abnormal liver/renal and cardiovascular function
  • Abnormal blood coagulation
  • Medical histories of peripheral vascular disease, alcohol or drug abuse, and mental illness.
  • Known or suspected intolerance or hypersensitivity to hyaluronan or its derivatives.
  • Concurrent use of systemic antiinflammatory drugs.
  • Clinical evidence of cancer.
  • Use of anticoagulant, fibrin glue, other thrombogenic agents, or any other anti-adhesion agent during the procedure.
  • Concurrent peritoneal grafting or tubal implantation.

About Bioregen Biomedical (Changzhou) Co., Ltd

Bioregen Biomedical (Changzhou) Co., Ltd. is a pioneering biotechnology company dedicated to advancing medical innovation through the development of regenerative therapies and biopharmaceuticals. With a strong focus on research and development, the company leverages cutting-edge technologies to create effective solutions for a range of health conditions. Committed to improving patient outcomes, Bioregen Biomedical collaborates with healthcare professionals and academic institutions to conduct rigorous clinical trials, ensuring the safety and efficacy of its products. The company's mission is to transform healthcare by delivering high-quality, evidence-based therapies that enhance the quality of life for patients worldwide.

Locations

Beijing, Beijing, China

Beijing, Beijing, China

Beijing, Beijing, China

Shijiazhuang, Hebei, China

Beijing, Beijing, China

Jinan, Shandong, China

Changsha, Hunan, China

Patients applied

0 patients applied

Trial Officials

Zhenyu Zhang, MD, PhD

Principal Investigator

Beijing Chao Yang Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials